Get the Stockscreener App
427.89
1.40%
5.89
After Hours:
427.89
Vertex Pharmaceuticals Inc stock is traded at $427.89, with a volume of 1.53M.
It is up +1.40% in the last 24 hours and up +7.71% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$422.00
Open:
$427.94
24h Volume:
1.53M
Relative Volume:
1.06
Market Cap:
$110.19B
Revenue:
$10.63B
Net Income/Loss:
$-479.80M
P/E Ratio:
-215.02
EPS:
-1.99
Net Cash Flow:
$-1.35B
1W Performance:
+3.94%
1M Performance:
+7.71%
6M Performance:
-12.95%
1Y Performance:
-1.64%
1-Day Range:
$423.49
$430.53
1-Week Range:
$415.13
$430.53
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals' SWOT analysis: stock outlook amid pipeline progress - MSN
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever - The Motley Fool
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Transform Wealth LLC - MarketBeat
Atwood & Palmer Inc. Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
MassMutual Private Wealth & Trust FSB Has $2.51 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Merit Financial Group LLC Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Zhang Financial LLC Boosts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Diversify Wealth Management LLC Grows Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
InTrack Investment Management Inc Has $878,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
J2 Capital Management Inc Invests $270,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
McKesson, Vertex Pharmaceuticals among top healthcare Quant picks before Q4 earnings - MSN
Avanza Fonder AB Takes $11.34 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
First Pacific Financial Has $695,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
RDA Financial Network Sells 2,375 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex's Pain Drug: Big Pharma's Next Major Success? - MSN
Empirical Asset Management LLC Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Gateway Investment Advisers LLC - MarketBeat
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
HHS says Vertex is ‘grasping at straws’ with Casgevy fertility suit - PharmaLive
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? - sharewise
Thurston Springer Miller Herd & Titak Inc. Purchases 673 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock - MSN
How Is The Market Feeling About Vertex Pharmaceuticals? - Benzinga
Burney Co. Has $15.21 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Assenagon Asset Management S.A. Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials - Yahoo Finance
40 Under 40: Mnwabisi Mbangata, Vertex Pharmaceuticals - MM+M Online
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine (VRTX) - Seeking Alpha
Vertex Pharmaceuticals' SWOT analysis: stock outlook balances innovation and valuation - Investing.com
Vertex Pharmaceuticals' (VRTX) "Outperform" Rating Reaffirmed at William Blair - MarketBeat
JPM25: Vertex CEO says pain is its next multi-billion franchise - FirstWord Pharma
Vertex Pharmaceuticals Incorporated : J.P. Morgan Healthcare Conference Presentation 2025 - Marketscreener.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Czech National Bank - MarketBeat
International Assets Investment Management LLC Sells 323,990 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings - Yahoo Finance
Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement - Yahoo Finance
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment - MSN
Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know - Yahoo Finance
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals - Benzinga
CCM Investment Advisers LLC Sells 7,770 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex out-licenses povetacicept to Zai Lab - The Pharma Letter
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore - BioSpace
Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials - MSN
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $460.00 by Analysts at Wells Fargo & Company - MarketBeat
Vertex Pharmaceuticals Incorporated and Zai Lab Limited Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore - Marketscreener.com
Pfizer Is ‘Too Low To Sell, Let Dividend Do Its Job': Jim CramerNVIDIA (NASDAQ:NVDA), Pfizer (NYSE:PFE) - Benzinga
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):